Tetra Pharm Technologies

A Biotech With A Robust Pipeline and Huge Market Potential

About this Event

Tetra Pharm Technologies is a Danish drug development company that has eleven pipeline candidates targeting some of today’s biggest health issues. In addition, they’ve developed a precision drug delivery platform that is so groundbreaking, it’s already generating revenue thanks to partnerships with international pharmaceutical companies.

Tetra Pharm Technologies focuses on improving health by treating the Central Nervous System (CNS). Their pipeline targets several CNS conditions including Chronic Pain, Obesity, and Mild Cognitive Impairment/Alzheimer’s. Their lead program, a non-opioid, non-addictive treatment for chronic pain will begin Phase 1 trials later this year. By 2027 the company expects to have 6 programs in the clinic.

One of the biggest challenges in treating CNS diseases is getting therapies to their targets. To that end, Tetra Pharm Technologies has developed Zyndikate, a modular drug delivery platform that provides precision targeting of multiple disease areas and accommodates oral, sub-lingual, nasal, and transdermal administration. The company has two signed contracts and several others in development. Eventually, they expect Zyndikate to generate enough revenue to sustain the development costs of their other programs.

Register to watch this online event with Tetra Pharm Technologies CEO, Martin Rose, to hear how their unique delivery platform and three lead assets represent a total addressable market of more than $300B.

Video On Demand

– Recorded

November 14

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.